目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNIT CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
2.2.1.1 Insights from primary sources
2.2.2 SEGMENTAL MARKET ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL CULTURE MARKET
4.2 NORTH AMERICA: CELL CULTURE MARKET, BY PRODUCT AND COUNTRY
4.3 CELL CULTURE MARKET SHARE, BY APPLICATION
4.4 CELL CULTURE MARKET SHARE, BY END USER
4.5 CELL CULTURE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing support and funding for cell-based research
5.2.1.2 Emerging cell culture technologies
5.2.1.3 Growing popularity of monoclonal antibodies and biosimilars
5.2.1.4 Increasing adoption of single-use technologies
5.2.1.5 Rise in product launches
5.2.1.6 Growth in advanced therapy medicinal products
5.2.1.7 Increasing incidence of infectious diseases
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell biology research
5.2.2.2 Limitations in producing high-density cell cultures
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for 3D cell culture
5.2.3.2 Growth opportunities in emerging economies
5.2.3.3 Increasing focus on next-generation therapeutics
5.2.4 CHALLENGES
5.2.4.1 Disposal of plastic consumables
5.2.4.2 Ethical concerns related to cell usage
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 INVESTMENT AND FUNDING SCENARIO
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Single-use technology
5.8.1.2 Flow cytometry
5.8.1.3 Microscopy
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 High-throughput screening
5.8.2.2 Mass spectrometry
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Microfluidics and organ-on-a-chip
5.8.3.2 3D bioprinting
5.9 PATENT ANALYSIS
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA
5.10.2 EXPORT DATA
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 TARIFF AND REGULATORY LANDSCAPE
5.12.1 TARIFF RELATED TO CELL CULTURE PRODUCTS
5.12.2 REGULATORY FRAMEWORK
5.12.2.1 North America
5.12.2.2 Europe
5.12.2.3 Asia Pacific
5.12.2.4 Latin America
5.12.2.5 Middle East & Africa
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 IMPACT OF AI/GENERATIVE AI ON CELL CULTURE PRODUCTS MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL OF AI IN CELL CULTURE APPLICATIONS
5.15.3 AI USE CASES
5.15.4 KEY COMPANIES IMPLEMENTING AI
5.15.5 FUTURE OF GENERATIVE AI IN CELL CULTURE ECOSYSTEM
5.16 IMPACT OF 2025 US TARIFF ON CELL CULTURE MARKET
5.16.1 INTRODUCTION
5.16.2 KEY TARIFF RATES
5.16.3 PRICE IMPACT ANALYSIS
5.16.4 IMPACT ON COUNTRY/REGION
5.16.4.1 US
5.16.4.2 Europe
5.16.4.3 Asia Pacific
5.16.5 IMPACT ON END-USE INDUSTRIES
5.16.5.1 Pharmaceutical & biotech companies
5.16.5.2 Hospitals & diagnostic laboratories
5.16.5.3 Academic & research institutes
5.16.5.4 Contract research organizations & contract development and manufacturing organizations

6 CELL CULTURE MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 SERA, MEDIA, AND REAGENTS
6.2.1.1 Media
6.2.1.1.1 Serum-free media
6.2.1.1.1.1 Enhanced control, reproducibility, and decreased batch-to-batch variability to aid growth
6.2.1.1.2 Classical media & salts
6.2.1.1.2.1 Need for efficient and scalable vaccine production to bolster growth
6.2.1.1.3 Stem cell culture media
6.2.1.1.3.1 Rising funding and support for stem cell-based research and therapy to augment growth
6.2.1.1.4 Chemically-defined media
6.2.1.1.4.1 Rising need for reproducibility, regulatory compliance, and precise control in cell culture systems to aid growth
6.2.1.1.5 Specialty media
6.2.1.1.5.1 Suitability for use in selective cell types in bioprocessing and biomanufacturing industries to boost market
6.2.1.1.6 Other media
6.2.1.2 Reagents
6.2.1.2.1 Growth factors
6.2.1.2.1.1 Need to regulate cell proliferation, differentiation, and migration to sustain growth
6.2.1.2.2 Supplements
6.2.1.2.2.1 Growing acquisitions and expansions by cell culture vendors to propel market
6.2.1.2.3 Buffers & chemicals
6.2.1.2.3.1 Ability to maintain stable pH levels to facilitate growth
6.2.1.2.4 Cell dissociation reagents
6.2.1.2.4.1 Ability to minimize cell stress and reduce cell damage to foster growth
6.2.1.2.5 Balanced salt solutions
6.2.1.2.5.1 Ability to maintain optimal physiological conditions for cell growth and experimentation to assist growth
6.2.1.2.6 Attachment & matrix factors
6.2.1.2.6.1 Rising adoption of 3D cell culture models to support growth
6.2.1.2.7 Antibiotics/Antimycotics
6.2.1.2.7.1 Ability to mitigate growth of contaminating bacteria, fungi, and mycoplasma to drive market
6.2.1.2.8 Cryoprotective reagents
6.2.1.2.8.1 Ability to preserve cell viability during freezing and thawing to aid growth
6.2.1.2.9 Contamination detection kits
6.2.1.2.9.1 Need for rapid identification of microbial contaminants to promote growth
6.2.1.2.10 Other reagents
6.2.1.3 Sera
6.2.1.3.1 Fetal bovine sera
6.2.1.3.1.1 Increasing role of fetal bovine sera in cell proliferation to favor growth
6.2.1.3.2 Adult bovine sera
6.2.1.3.2.1 Cost-effectiveness to contribute to growth
6.2.1.3.3 Other animal sera
6.2.2 VESSELS
6.2.2.1 Cell factory systems/cell stacks
6.2.2.1.1 Efficient and scalable solutions for large-scale expansion to drive adoption
6.2.2.2 Roller/roux bottles
6.2.2.2.1 Scalability, cost-effectiveness, and ease of handling to support growth
6.2.2.3 Flasks
6.2.2.3.1 Growing advancements in cell culture flasks to boost market
6.2.2.4 Multiwell plates
6.2.2.4.1 Increasing adoption of multiwell plates in high-throughput or high-content screening to aid growth
6.2.2.5 Petri dishes
6.2.2.5.1 Rising use of petri dishes as sterile containers to sustain growth
6.2.3 ACCESSORIES
6.2.3.1 Reduced preparation time and equipment performance improvements to augment growth
6.3 EQUIPMENT
6.3.1 BIOREACTORS
6.3.1.1 Conventional bioreactors
6.3.1.1.1 Utilization in large-scale manufacturing of drugs to drive market
6.3.1.2 Single-use bioreactors
6.3.1.2.1 Lower operational costs and increased flexibility to boost market
6.3.2 STORAGE EQUIPMENT
6.3.2.1 Refrigerators & freezers
6.3.2.1.1 Increasing need for storage solutions to propel market
6.3.2.2 Cryostorage systems
6.3.2.2.1 Benefits of long-term preservation of cell cultures to support growth
6.3.3 OTHER EQUIPMENT
6.3.3.1 Filtration systems
6.3.3.1.1 Growing use in bioprocessing industry to boost market
6.3.3.2 Cell counters
6.3.3.2.1 Growing adoption of automated cell counters to propel market
6.3.3.3 Carbon dioxide incubators
6.3.3.3.1 Increasing focus of research institutes on developing lab-scale incubators to drive market
6.3.3.4 Centrifuges
6.3.3.4.1 Increasing demand for bioproduction applications to drive adoption of centrifuges
6.3.3.5 Autoclaves
6.3.3.5.1 Reliance on single-use labware and equipment to affect demand for autoclaves
6.3.3.6 Microscopes
6.3.3.6.1 Enhanced imaging capabilities to augment growth
6.3.3.7 Biosafety cabinets
6.3.3.7.1 Increasing launches of biosafety cabinets to promote growth
6.3.3.8 Other supporting equipment

7 CELL CULTURE MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 BIOPHARMACEUTICAL PRODUCTION
7.2.1 MONOCLONAL ANTIBODY PRODUCTION
7.2.1.1 Increasing approval and launch of mAb candidates to amplify growth
7.2.2 VACCINE PRODUCTION
7.2.2.1 Rising incidence of infectious diseases to support growth
7.2.3 OTHER THERAPEUTIC PROTEIN PRODUCTION
7.3 DIAGNOSTICS
7.3.1 GROWING ADVANCEMENTS AND ADOPTION OF NEW TECHNIQUES TO FUEL MARKET
7.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE
7.4.1 CELL & GENE THERAPY
7.4.1.1 Rising investments in developing cell-based immunotherapies to foster growth
7.4.2 OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS
7.5 DRUG SCREENING & DEVELOPMENT
7.5.1 INCREASING FOCUS ON BIOLOGIC DRUGS TO FAVOR GROWTH
7.6 OTHER APPLICATIONS

8 CELL CULTURE MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING DEMAND FOR CULTURE CELL LINES FOR DRUG SCREENING AND R&D TO AID GROWTH
8.3 HOSPITALS & DIAGNOSTIC LABORATORIES
8.3.1 GROWING USE OF CELL CULTURE FOR CELLULAR PHYSIOLOGY, DISEASE MECHANISMS, AND DRUG RESPONSES TO BOOST MARKET
8.4 RESEARCH & ACADEMIC INSTITUTES
8.4.1 RISING FUNDING ACTIVITIES TO CONTRIBUTE TO GROWTH
8.5 OTHER END USERS

9 CELL CULTURE MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Advanced healthcare infrastructure and government support to bolster growth
9.2.3 CANADA
9.2.3.1 Increasing funding and investments for cell-based therapies to boost market
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Rising R&D investments and strategic alliances to promote growth
9.3.3 UK
9.3.3.1 Growth in life science industry and favorable government investments to drive market
9.3.4 FRANCE
9.3.4.1 Rising number of cell-based research projects to enhance growth
9.3.5 ITALY
9.3.5.1 Strong government support for R&D activities to spur growth
9.3.6 SPAIN
9.3.6.1 Booming biotechnology industry to bolster growth
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Rising focus on stem cell & regenerative medicine research to expedite growth
9.4.3 JAPAN
9.4.3.1 Rising government initiatives and increasing investments in biotech to intensify growth
9.4.4 INDIA
9.4.4.1 Favorable government support and expansion by key cell culture players to augment growth
9.4.5 SOUTH KOREA
9.4.5.1 Growing pharmaceutical sector to drive market
9.4.6 AUSTRALIA
9.4.6.1 Increasing prevalence of chronic diseases to accelerate growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Rising prevalence of cancer and related research activities to support growth
9.5.3 MEXICO
9.5.3.1 Increasing advancements in biotechnology industry to spur growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia
9.6.2.1.1 Increasing focus of key players on expansion to drive market
9.6.2.2 UAE
9.6.2.2.1 Increasing shift from importing to manufacturing pharmaceuticals to boost market
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RISING GRANTS AND FUNDING FOR CELL AND GENE THERAPY PRODUCTS TO FOSTER GROWTH
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL CULTURE MARKET
10.3 REVENUE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY VALUATION AND FINANCIAL METRICS
10.6 BRAND/PRODUCT COMPARISON
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.7.5.1 Company footprint
10.7.5.2 Region footprint
10.7.5.3 Product footprint
10.7.5.4 Application footprint
10.7.5.5 End-user footprint
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.8.5.1 Detailed list of key startups/SMEs
10.8.5.2 Competitive benchmarking of key startups/SMEs
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS

11 COMPANY PROFILES
11.1 INTRODUCTION
11.2 KEY PLAYERS
11.2.1 THERMO FISHER SCIENTIFIC INC.
11.2.1.1 Business overview
11.2.1.2 Products offered
11.2.1.3 Recent developments
11.2.1.3.1 Product launches
11.2.1.3.2 Deals
11.2.1.3.3 Expansions
11.2.1.4 MnM view
11.2.1.4.1 Key strengths
11.2.1.4.2 Strategic choices
11.2.1.4.3 Weaknesses and competitive threats
11.2.2 DANAHER
11.2.2.1 Business overview
11.2.2.2 Products offered
11.2.2.3 Recent developments
11.2.2.3.1 Product launches
11.2.2.3.2 Deals
11.2.2.3.3 Expansions
11.2.2.3.4 Other developments
11.2.2.4 MnM view
11.2.2.4.1 Key strengths
11.2.2.4.2 Strategic choices
11.2.2.4.3 Weaknesses and competitive threats
11.2.3 MERCK KGAA
11.2.3.1 Business overview
11.2.3.2 Products offered
11.2.3.3 Recent developments
11.2.3.3.1 Product launches
11.2.3.3.2 Deals
11.2.3.3.3 Expansions
11.2.3.4 MnM view
11.2.3.4.1 Key strengths
11.2.3.4.2 Strategic choices
11.2.3.4.3 Weaknesses and competitive threats
11.2.4 SARTORIUS AG
11.2.4.1 Business overview
11.2.4.2 Products offered
11.2.4.3 Recent developments
11.2.4.3.1 Product launches
11.2.4.3.2 Deals
11.2.4.3.3 Expansions
11.2.5 CORNING INCORPORATED
11.2.5.1 Business overview
11.2.5.2 Products offered
11.2.5.3 Recent developments
11.2.5.3.1 Product launches
11.2.5.3.2 Deals
11.2.6 FUJIFILM HOLDINGS CORPORATION
11.2.6.1 Business overview
11.2.6.2 Products offered
11.2.6.3 Recent developments
11.2.6.3.1 Product launches
11.2.6.3.2 Deals
11.2.6.3.3 Expansions
11.2.6.3.4 Other developments
11.2.7 BD
11.2.7.1 Business overview
11.2.7.2 Product offered
11.2.7.3 Recent developments
11.2.7.3.1 Product Launches
11.2.7.3.2 Deals
11.2.8 EPPENDORF SE
11.2.8.1 Business overview
11.2.8.2 Products offered
11.2.8.3 Recent developments
11.2.8.3.1 Product launches
11.2.8.3.2 Deals
11.2.8.3.3 Expansions
11.2.9 LONZA
11.2.9.1 Business overview
11.2.9.2 Products offered
11.2.9.3 Recent developments
11.2.9.3.1 Product launches
11.2.9.3.2 Deals
11.2.10 GETINGE
11.2.10.1 Business overview
11.2.10.2 Products offered
11.2.10.3 Recent developments
11.2.10.3.1 Product launches
11.2.10.3.2 Deals
11.2.10.3.3 Expansions
11.2.11 AGILENT TECHNOLOGIES, INC.
11.2.11.1 Business overview
11.2.11.2 Products offered
11.2.11.3 Recent developments
11.2.11.3.1 Product launches
11.2.11.3.2 Deals
11.2.11.3.3 Expansions
11.2.12 HIMEDIA LABORATORIES
11.2.12.1 Business overview
11.2.12.2 Products offered
11.2.13 BIO-TECHNE
11.2.13.1 Business overview
11.2.13.2 Products offered
11.2.13.3 Recent developments
11.2.13.3.1 Product launches
11.2.13.3.2 Deals
11.2.13.3.3 Expansions
11.3 OTHER PLAYERS
11.3.1 MILTENYI BIOTEC
11.3.2 STEMCELL TECHNOLOGIES
11.3.3 SOLIDA BIOTECH GMBH
11.3.4 CAISSON LABSn
11.3.5 PROMOCELL GMBH
11.3.6 INVIVOGEN
11.3.7 PAN-BIOTECH
11.3.8 CELLEXUS
11.3.9 MEISSNER FILTRATION PRODUCTS, INC.
11.3.10 ADOLF KUHNER AG
11.3.11 ADVANCION CORPORATION
11.3.12 BIOSPHERIX LLC

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS n